Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04JZH
|
||||
| Former ID |
DIB001125
|
||||
| Drug Name |
PF-01247324
|
||||
| Synonyms |
PF-01247324; Nav1.8 blockers (pain); Nav1.8 blockers (pain), Pfizer; Voltage-gated sodium channel 1.8 blockers (pain), Pfizer
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Pain [ICD9: 338, 356.0, 356.8,780; ICD10:G64, G90.0, R52, G89] | Phase 1 | [1] | ||
| Company |
Pfizer Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C13H10Cl3N3O
|
||||
| InChIKey |
HPIUHDCRVYDAEJ-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Voltage-gated sodium channel subunit alpha Nav1.8 | Target Info | Blocker | [2] | |
| Reactome | Interaction between L1 and Ankyrins | ||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8521). | ||||
| REF 2 | Oral Administration of PF-01247324, a Subtype-Selective Nav1.8 Blocker, Reverses Cerebellar Deficits in a Mouse Model of Multiple Sclerosis. PLoS One. 2015; 10(3): e0119067. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.